Clinical Trial Search

Primary: Percentage of Participants With GVHD/Relapse or Progression-free Survival (GRFS) — 35.5; 27.2; 44.1 percentage of participants

Primary: Number of Complete Response (CR) at Day 28 of Therapy — 12; 27; 25; 16 participants

Primary: Percentage of Participants With Evidence of Acute Graft Versus Host Disease (aGVHD), Post Transplant — 43; 89 percentage of participants

Primary: GVHD-free Relapse-Free Survival — 19.3 percentage of subjects

Primary: GVHD-free Survival — 60; 69; 59; 47 participants

Primary: The Cumulative Incidence of Grade II-IV Acute GVHD up to Day 100 After Stem Cell Infusion — 32 Percentage of participants

Primary: Number of Participants With Complete Response (CR) — 34 Participants

Primary: Number of Patients With Grades II-IV Acute GVHD — 39; 22; 3 Participants

Primary: Incidence of Acute GVHD — 45.0 percentage of participants

Primary: Mean Cumulative Prednisone Dose (mg/kg) Over 42 Days From the Start of Treatment — 22.2; 27.1; 38.4; 41.3 milligrams per kilogram — p=0.08

Primary: Distribution of Acute GVHD Grades (MAGIC Criteria) at Time of PET/CT Scan — 0; 2; 0; 0 Participants

Primary: Number of Participants With an Overall Response at Week 28 — 20; 14 Participants — p=0.373

Primary: Proportion of Participants With Treatment Success — 33; 35; 33; 37 Participants — p=0.63

Primary: Number (Percentage) of Patients at Each Dosing Cohort Who Experience no Toxicity and in Whom Graft Versus Host Disease (GVHD) is Stable or Improved — 6; 2; 2 Participants

Primary: Day 56 Treatment Success — 57; 72; 43; 47 percentage of participants

Primary: The Percentage of Patients Who Progress Within 28 Days of Initiation of Etanercept Treatment — 29 percentage of patients

Primary: Significant Clinical Response — 9; 10 participants

Primary: Response to Bortezomib (VELCADE®) — 2; 2; 4 participants

Primary: Incidence of Clinician-diagnosed Chronic GVHD at One and Two Years — 38; 48 percentage of participants

Primary: Number of Patients Who Achieve CR or PR by Day 28 of Treatment — 62 Participants

Primary: Number of Subjects Not Experiencing Grade II-IV Acute Graph Versus Host Disease (aGVHD) — 3; 18; 0 Participants

Primary: Grades II-IV aGVHD — 11 Participants

Primary: Acute Graft vs Host Disease (GvHD) — 2.7 percentage of participants

Primary: Overall Response (Complete Response + Partial Response + Other) — 7; 2; 0; 0 participants

Primary: Overall Response Rate After a 15 Week Course of Bortezomib Plus Prednisone in Patients With cGVHD — 2; 14; 1; 2 participants

Primary: Rate of Grades II-IV Acute GVHD-free Survival — 67; 62 percentage of participants

Primary: The Number of Participants That Experience Grade 2-4 Acute GVHD (Graft Versus Host Disease) by Day 100 — 2 participants

Primary: Chronic GVHD Requiring Systemic Immunosuppressive Treatment — 16 percent of patients

Primary: Maximum Tolerated Dose of Ofatumumab — 1000 mg

Primary: Incidence of Grade III/IV GVHD — 2; 4 Participants